Please assess the completion status of the following clinical trial:

Trial Title: Phase I Study of HMPL-523+Azacitidine in Elderly Patients With Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject must have confirmation of AML by WHO criteria, except for APL (M3)~2. Subject must be ≥ 65 years of old and be ineligible for treatment with a standard cytarabine and anthracycline induction regimen due to co-morbidity or other factors~3. Subject must have received no prior treatment for AML with the exception of hydroxyurea~4. ECOG performance status of 0-1. For dose-expansion stage, ECOG PS of 2 will also be eligible~Exclusion Criteria:~1. Subject has received treatment of hypomethylating agent and/or chemo therapeutic agent for MDS or MPN~2. Subject has known active CNS involvement or extramedullary sarcoma from AML~3. Subject has favorable risk cytogenetics as categorized by the NCCN Guidelines Version 1, 2018 for Acute Myeloid Leukemia, such as inv(16) or t(16;16) or t(8;21) or t(15;17)~4. Subject has a white blood cell count \> 25 × 109/L (Hydroxyurea is permitted to meet this criterion)~5. Subject with serum amylase or lipase \> the ULN~6. Subject is known to be positive for hepatitis B or C infection with the exception of those with an undetectable viral load.~7. Subject who don't have enough liver or renal function~8. Subject with New York Heart Association (NYHA) Class III or greater congestive heart failure~9. Subject received herbal therapy ≤ 1 week prior to initiation of study treatment~10. Subject received prior treatment with any SYK inhibitors (Fostamatinib) or FLT3 inhibitor (Quizartinib) or multi-target inhibitor with SYK or FLT3 inhibition activity (Midostaurin)

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HMPL-523 & Azacitidine (Type: EXPERIMENTAL): HMPL-523 will be taken orally once daily continuously through a 28-days Cycle of study treatment. Azacitidine will be administered subcutaneously, beginning on Day 1 through Day 7 of each Cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).